NEW HAVEN, Conn., September 03, 2025--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for ...
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds ...
On Tuesday, KeyBanc reaffirmed its Overweight rating and $12.00 price target for Recursion Pharmaceuticals (NASDAQ:RXRX), following the announcement of Phase 2 trial results for REC-994. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback